Please assess the completion status of the following clinical trial:

Trial Title: Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(I) 18 - 80 years of age, (II) diagnosed as stable coronary artery disease or acute coronary syndrome during admission (III) undergoing clinically indicated coronary angiography and identified with at least one intermediate lesion (50%-70% diameter stenosis) on de novo coronary arteries, (IV) have an elevated LDL-C values (LDL-C≥100 mg/dL) despite taken rosuvastatin 10 mg/day or atorvastatin 20 mg/day for 2-4 weeks after initiation or with maximally tolerated statin therapy, (V) able to provide written, informed consent.~Exclusion Criteria:~1. Patients who have been treated previously with at least one dose of any anti-PCSK9 monoclonal antibody~2. received target vessel revascularization~3. Known hypersensitivity or have contraindications to any anti-PCSK9 monoclonal antibody or statins~4. Unable to receive OCT imaging tests~5. Known history of hemorrhagic stroke~6. Currently under treatment for cancer~7. Baseline triglyceride \> 400 mg/dl~8. Patients with severe liver or renal dysfunction~9. Pregnant or breast-feeding women~10. Considered by the investigator as inappropriate for this study for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- alirocumab plus statin (Type: EXPERIMENTAL): Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
- standard statin therapy (Type: ACTIVE_COMPARATOR): Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target \<100 mg/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).